Use of nivolumab (N) and cabozantinib (C) for treatment of the metastatic renal cell carcinoma (mRCC) in the Veneto region: Results of AMOUR study.

Marco Maruzzo,Alberto Bortolami,Dario Palleschi,Andrea Zivi,Maurizio Nicodemo,Donata Sartori,Rocco De Vivo,Fable Zustovich,Davide Bimbatti,Davide Pastorelli,G. Vultaggio,Mariella Sorarů,Melissa Ballestrin,Giulia Zanchetta,Caterina Modonesi,Paola Randisi,Carmen Barile,Gino Perri,Umberto Basso,Vittorina Zagonel

Use of nivolumab (N) and cabozantinib (C) for treatment of the metastatic renal cell carcinoma (mRCC) in the Veneto region: Results of AMOUR study.

2021

290Background: Second (2L) or third-line (3L) treatment options for mRCC have dramatically changed in the last years. The standard of care as per Italian Regulatory Agencies approvals is N or C. To...

Keywords:

Oncology
treatment options
standard of care
Internal medicine
Cabozantinib
Renal cell carcinoma
Nivolumab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations